GlobeNewswire by notified

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS

Share

Regulated Information - Denominator

Atlas Special Opportunities, LLChas converted 12convertible bonds in Oxurion resulting in a EUR 300,000capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5billion.

Leuven, BELGIUM,Boston, MA, USMarch 31, 202307.00 PM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), announces the below information, following the issuance of 28,942,629 new ordinary shares on March 28, 2023, for a total amount of EUR 300,000, as the result of the conversion of 12 convertible bonds, pursuant to the Capital Commitment entered into with Atlas Special Opportunities, LLC.

Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 632,659,186 outstanding ordinary shares carrying voting rights (compared to 603,716,557 outstanding ordinary shares previously). This number will be used as the denominator for the calculation of the percentages of shareholdings.

Therefore, Oxurion publishes the following updated information:

  • Share capital (EUR)
78,206,161.32
  • Total number of securities with voting rights (all ordinary shares)
632,659,186
  • Total number of ordinary shares (= denominator)
632,659,186
  • Number of outstanding, granted rights to subscribe to securities carrying voting rights not yet issued:
  • 694,000 subscription rights (“SRs”) issued on November 20, 2017, entitling their holders to subscribe to a total number of 694,000 securities carrying voting rights (all ordinary shares);
  • 60,000 SRs issued on December 23, 2020, entitling their holders to subscribe to a total number of 60,000 securities carrying voting rights (all ordinary shares);
  • 976,874 SRs issued on April 14, 2021, entitling their holders to subscribe to a total number of 976,874 securities carrying voting rights (all ordinary shares);
  • 534,688 SRs issued on September 22, 2021, entitling their holders to subscribe to a total number of 534,688 securities carrying voting rights (all ordinary shares);
  • 582,248 SRs issued on December 30, 2021, entitling their holders to subscribe to a total number of 582,248 securities carrying voting rights (all ordinary shares);
  • 92 convertible bonds issued on March 14, 2023, entitling its holder, Atlas Special Opportunities, LLC, to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions of these convertible bonds pursuant to the Subscription Agreement entered into between the Company and Atlas Special Opportunities, LLC on March 1, 2023; and
  • 100 convertible bonds issued on December 20, 2021, entitling their holders (Kreos Capital VI (UK) Limited, Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P.) to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions of these convertible bonds as attached to the Agreement for the provision of a Loan Facility entered into between the Company, Kreos Capital VI (UK) Limited, Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P., on November 21, 2021 (as amended from time to time).

END

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV
Tom Graney
Chief Executive Officer
Tel: +32 16 75 13 10
tom.graney@oxurion.com



Michaël Dillen
Chief Business Officer
Tel: +32 16 75 13 10
michael.dillen@oxurion.com
US
Conway Communications
Mary T. Conway
mtconway@conwaycommsir.com





ICR Westwicke
Christopher Brinzey
Tel: +1 617 835 9304
chris.brinzey@westwicke.com



1Press release Oxurion, 02/03/2023

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Sai Life Sciences reaffirms commitment to Sustainability, charts out SDGs to be achieved by FY276.6.2023 12:41:52 CEST | Press release

HYDERABAD, India, June 06, 2023 (GLOBE NEWSWIRE) -- On the World Environment Day 2023, Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization (CRO-CDMO), announced its renewed Sustainable Development Goals (SDG) charting out the roadmap to achieve specific environmental, social and governance (ESG) targets by the financial year ending March 31, 2027. Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said, “Our renewed Sustainable Development Goals reflect a coming of age of our Sustainability journey. The learnings and successes from the first edition have shaped our aspiration for this phase and signify a certain boldness that comes with persevering unabated on a chosen path. While Sustainability has always been at the heart of our ethos at Sai Life Sciences, I must thank all our customers and partners for inspiring us raise the bar each day.” Sai Life Sciences first charted out its SDGs in 2019 with a three-year ti

Calibre Announces the Publication of its 2022 Sustainability Report, Demonstrating Commitment to Transparency and Responsible Practices6.6.2023 12:00:55 CEST | Press release

VANCOUVER, British Columbia, June 06, 2023 (GLOBE NEWSWIRE) -- Calibre Mining Corp. (TSX: CXB; OTCQX: CXBMF) (“Calibre” or the “Company”) is pleased to announce the publication of its 2022 Sustainability Report (“the Report”). The Report outlines Calibre’s 2022 progress and achievements, provides guidance for the Company’s Environmental, Social and Governance (“ESG”) performance, and underscores Calibre’s unwavering commitment to transparency, accountability and responsible business practices. Calibre acknowledges that incorporating sustainability into its business strategy is essential to our long-term success. In 2022, the Company saw record production for the third consecutive year. Calibre’s increasing focus on sustainability practices and robust ESG performance ensures that such accomplishments are achieved in ways that are ethical, transparent, accountable, and respectful of the rights of others. Darren Hall, President and Chief Executive Officer, stated: “At Calibre, we recogniz

Noted Vaccine Researcher Thomas P. Monath Awarded Sabin’s Gold Medal; Cameroon Physician Sangwe Clovis Nchinjoh Receives Rising Star Award6.6.2023 12:00:00 CEST | Press release

WASHINGTON, June 06, 2023 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today awarded the 30th Albert B. Sabin Gold Medal Award to Thomas P. Monath, MD, and its Rising Star Award to Sangwe Clovis Nchinjoh, MD, MPH, in a ceremony at Washington D.C.’s National Academy of Sciences building. Dr. Monath was selected for the Gold Medal for his more than four decades of commitment to advancing knowledge of arboviruses and vaccine research and development (R&D) that contributed to the development of several innovative vaccines including those for Ebola Zaire, smallpox, dengue, Japanese encephalitis and West Nile. The Gold Medal, celebrating three decades of recognition, is Sabin’s highest scientific honor. It is given annually to a distinguished member of the global health community who has made exceptional contributions to vaccinology or a complementary field. Past award recipients include leaders of vaccinology and vaccine advocacy such as Drs. Barney Graham, Carol Baker, Bill Foege, Anne

PRESS RELEASE: SSH launches OpenSSH support service for multi-platform SSH environments6.6.2023 12:00:00 CEST | Press release

Helsinki, Finland - June 6, 2023 - To resolve various customer support problems regarding OpenSSH implementations, SSH has launched a support service for OpenSSH. As a result, customers benefit from high-quality SSH support services also for the open-source variant of SSH software. OpenSSH will be supported on Windows and Red Hat Linux platforms. The SSH protocol is a secure network protocol used to establish encrypted and secure remote connections and transfer data between different systems. OpenSSH is an open-source implementation of the SSH protocol. It was initially released as a free version of SSH’s Tectia product. As an open-source product, OpenSSH is popular, especially as SSH client software. However, its usage in critical corporate environments has been partly limited due to a lack of high-quality support services or support from a single source for all SSH clients. Without proper support services, customers often invest in in-house OpenSSH expertise, resulting in increased o

Novo Nordisk A/S – Share repurchase programme6.6.2023 11:56:26 CEST | Press release

Bagsværd, Denmark, 6June 2023 – On 9 May 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023. Under the programme initiated 9 May 2023, Novo Nordisk will repurchase B shares for an amount up to DKK 5.8 billion in the period from 10 May 2023 to 8 August 2023. Since the announcement 30 May of the programme, the following transactions have been made: Number of B sharesAverage purchase priceTransaction value, DKKAccumulated, last announcement906,0001,042,810,01330 May 202382,7001,123.3192,897,99931 May 202385,0001,117.9295,023,0001 June 202385,0001,109.7994,332,2702 June 202390,0001,076.5596,889,206Accumulated under the